Calcium Folinate Treatment of Spastic Paraplegia 56

Recruiting now · Early Phase 1

Conditions studied: Hereditary Spastic Paraplegia

In brief

SPG56 is one of the complicated and early-onset HSP subtypes caused by genetic mutations in CYP2U1. So far, there is no standardized and specific clinical therapy for SPG56. The goal of this clinical trial is to explore the efficacy and safety of calcium folinate in the treatment of SPG56 patients. This study is prospective, open-label and single arm and this trial will last for 6 years. A total of 10 patients will participate and they will receive calcium folinate treatment and professional clinical evaluation regularly.

Key facts

Study ID
NCT06478238
Run by
Shanghai 6th People's Hospital
People needed
10
Starts
2024-07-01
Expected to finish
2030-05-31
Last updated by the study team
2024-06-27

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.